Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.53
+0.2%		$62.43
$49.26
▼
$70.98
$12.88B0.242.07 million shs2.30 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$110.19
-0.5%		$90.05
$61.22
▼
$111.15
$12.51B0.881.85 million shs956,601 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$39.86
-0.3%		$37.54
$23.23
▼
$42.68
$3.50B-0.071.06 million shs447,696 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$541.08
-0.3%		$529.33
$393.61
▼
$615.00
$12.50B-0.98342,467 shs177,162 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-0.81%+1.75%+9.40%+17.02%+12.63%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+1.00%+3.59%+33.08%+54.84%+48.04%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-0.50%-4.31%+10.69%+41.29%+55.16%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.79%-0.20%+6.91%+11.42%+24.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.53
+0.2%		$62.43
$49.26
▼
$70.98
$12.88B0.242.07 million shs2.30 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$110.19
-0.5%		$90.05
$61.22
▼
$111.15
$12.51B0.881.85 million shs956,601 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$39.86
-0.3%		$37.54
$23.23
▼
$42.68
$3.50B-0.071.06 million shs447,696 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$541.08
-0.3%		$529.33
$393.61
▼
$615.00
$12.50B-0.98342,467 shs177,162 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-0.81%+1.75%+9.40%+17.02%+12.63%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+1.00%+3.59%+33.08%+54.84%+48.04%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-0.50%-4.31%+10.69%+41.29%+55.16%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.79%-0.20%+6.91%+11.42%+24.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.74
Moderate Buy$89.1734.29% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.62
Moderate Buy$91.20-17.22% Downside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.82
Moderate Buy$50.8727.73% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6429.66% Upside

Current Analyst Ratings Breakdown

Latest IDYA, BMRN, MDGL, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$115.00
9/1/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/1/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/1/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$88.00 ➝ $90.00
9/1/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$42.00
8/31/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$104.00 ➝ $105.00
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$59.00 ➝ $60.00
8/26/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$88.00
8/19/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$98.00
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.99$2.83 per share23.47$32.66 per share2.03
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.66B7.52$4.79 per share22.98$1.26 per share87.43
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$218.71M16.00N/AN/A$13.65 per share2.92
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M13.01N/AN/A$22.67 per share23.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37179.4812.180.482.14%5.32%3.69%10/26/2026 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.3532.8811.900.4324.86%260.98%23.91%11/2/2026 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$113.70M-$1.94N/AN/AN/A-75.93%-16.73%-15.34%11/9/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A97.22N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)

Latest IDYA, BMRN, MDGL, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/6/2026Q2 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.79$2.28+$0.49$1.90$402.28 million$481.00 million
8/4/2026Q2 2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$1.06-$1.22-$0.16-$1.22$8.02 million$8.86 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
2.71
2.31
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
10.45
10.45
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94

Institutional Ownership

CompanyInstitutional Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%

Insider Ownership

CompanyInsider Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4.70%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390113.50 million110.66 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.86 million83.73 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable

Recent News About These Companies

Legal & General Group Plc Invests $6.63 Million in Madrigal Pharmaceuticals, Inc. $MDGL
September 3 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-663-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-03/
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
September 2 at 11:08 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference-1036515145
Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference
September 2 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355104/0/en/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference.html
Two Sigma Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
September 1 at 5:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-two-sigma-securities-llc-makes-new-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-01/
The Manufacturers Life Insurance Company Invests $6.55 Million in Madrigal Pharmaceuticals, Inc. $MDGL
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-invests-655-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-31/
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Analysts
August 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30993555
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Analysts
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-madrigal-pharmaceuticals-inc-nasdaq-mdgl-given-consensus-rating-of-moderate-buy-by-analysts-2026-08-31/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Wellington Management Group LLP
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madrigal-pharmaceuticals-inc-mdgl-shares-bought-by-wellington-management-group-llp-2026-08-30/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Algert Global LLC
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madrigal-pharmaceuticals-inc-mdgl-shares-sold-by-algert-global-llc-2026-08-30/
Hsbc Holdings PLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-makes-new-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-29/
Canada Pension Plan Investment Board Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-canada-pension-plan-investment-board-takes-position-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-29/
Bamco Inc. NY Makes New $2.42 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bamco-inc-ny-makes-new-242-million-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-28/
Seven Fleet Capital Management LP Makes New $2.67 Billion Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-makes-new-267-billion-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-27/
Castleark Management LLC Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-castleark-management-llc-buys-new-stake-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-27/
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.1% - Here's What Happened
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-madrigal-pharmaceuticals-nasdaq-mdgl-trading-up-71-heres-what-happened-2026-08-26/
Paulson & CO. Inc. Invests $719.52 Million in Madrigal Pharmaceuticals, Inc. $MDGL
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-paulson-co-inc-invests-71952-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-26/
Jupiter Topco LLC Buys Shares of 1,936,099 Madrigal Pharmaceuticals, Inc. $MDGL
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-buys-shares-of-1936099-madrigal-pharmaceuticals-inc-mdgl-2026-08-26/
J. Goldman & Co LP Buys New Shares in Madrigal Pharmaceuticals, Inc. $MDGL
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-j-goldman-co-lp-buys-new-shares-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-26/
9,980 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by EFG International AG
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-9980-shares-in-madrigal-pharmaceuticals-inc-mdgl-bought-by-efg-international-ag-2026-08-26/
128,520 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by Bank of New York Mellon Corp
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-128520-shares-in-madrigal-pharmaceuticals-inc-mdgl-acquired-by-bank-of-new-york-mellon-corp-2026-08-26/
Nan Fung Group Holdings Ltd Buys New Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nan-fung-group-holdings-ltd-buys-new-holdings-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-25/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$66.53 +0.10 (+0.15%)
As of 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$110.19 -0.57 (-0.51%)
As of 04:00 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$39.86 -0.11 (-0.28%)
As of 04:00 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$541.08 -1.53 (-0.28%)
As of 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas